{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Chen JJ"],"pubmed_abstract":["A severe immune response in patients with coronavirus disease 2019 (COVID-19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)-6 signaling may improve outcomes and the survival of patients suffering from COVID-19. Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL-6R targeting inhibitors for severe and critical COVID-19 treatment."],"journal":["Experimental and therapeutic medicine"],"pagination":["24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7690237"],"repository":["biostudies-literature"],"pubmed_title":["Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review)."],"pmcid":["PMC7690237"],"pubmed_authors":["Xu L","Zhang LN","Chen JJ","Ji K","Hou H"],"additional_accession":[]},"is_claimable":false,"name":"Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).","description":"A severe immune response in patients with coronavirus disease 2019 (COVID-19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)-6 signaling may improve outcomes and the survival of patients suffering from COVID-19. Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL-6R targeting inhibitors for severe and critical COVID-19 treatment.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-22T00:42:50.188Z","creation":"2025-04-05T19:37:08.491Z"},"accession":"S-EPMC7690237","cross_references":{"pubmed":["33262810"],"doi":["10.3892/etm.2020.9456"]}}